{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:45:19Z","timestamp":1785422719765,"version":"3.56.0"},"reference-count":118,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior\u2014Brasil","doi-asserted-by":"crossref","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"https:\/\/ror.org\/00x0ma614","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>\u03b1-synuclein (\u03b1-syn) aggregation in dopaminergic neurons is a central event in Parkinson\u2019s disease (PD) pathogenesis. Immunotherapeutic strategies targeting \u03b1-syn, including passive and active approaches, aim to inhibit aggregation, propagation, and toxicity of pathological species while promoting their clearance via immune mechanisms. This review summarizes \u03b1-syn directed immunotherapies evaluated in in silico, in vitro, and in vivo models, as well as early phase clinical trials, focusing on how epitope selection and antibody formats influence efficacy, safety, and target engagement. Data on monoclonal antibody, peptide, and protein-based vaccines, and structure-guided immunogens were analyzed, integrating behavioral, neuropathological, proteomic, and structural outcomes alongside biomarker development for \u03b1-syn species in cerebrospinal fluid and peripheral compartments. Clinical evidence indicates that several candidates induce sustained anti-\u03b1-syn antibody responses with acceptable safety profiles and signs of pharmacodynamic engagement, including reductions in free or oligomeric \u03b1-syn. However, consistent long-term clinical benefits remain unproven, highlighting the gap between preclinical success and disease modification in humans. Advances in structural biology and proteomics support rational epitope selection and improved immunogen design, reinforcing \u03b1-syn-targeted immunotherapy as a promising yet experimental strategy for PD, and highlighting the need for mechanistically oriented, biomarker-driven clinical trials initiated in well-characterized prodromal and early-stage cohorts.<\/jats:p>","DOI":"10.3390\/molecules31122036","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:48:35Z","timestamp":1781138915000},"page":"2036","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u03b1-Synuclein-Targeted Immunotherapies in Parkinson\u2019s Disease: In Silico, In Vitro and Clinical Perspectives"],"prefix":"10.3390","volume":"31","author":[{"given":"Tatiane B.","family":"Santos","sequence":"first","affiliation":[{"name":"Graduate Program in Biosciences and Health, Northeast Biotechnology Network (RENORBIO), Tiradentes University, Farol\u00e2ndia Campus, Av. Murilo Dantas, 300, Aracaju 49032-490, SE, Brazil"},{"name":"Laboratory of Morphology and Experimental Pathology, Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49032-490, SE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7363-3752","authenticated-orcid":false,"given":"Tatiane de O. X.","family":"Machado","sequence":"additional","affiliation":[{"name":"Department of Agroindustry, Federal Institute of Sert\u00e3o Pernambucano, Campus Petrolina Zona Rural, PE 647, Km 22, PISNC N4, Petrolina 56302-970, PE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Henrique S.","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Laboratory of Morphology and Experimental Pathology, Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49032-490, SE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willamys S.","family":"Correa","sequence":"additional","affiliation":[{"name":"Laboratory of Morphology and Experimental Pathology, Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49032-490, SE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena A. C.","family":"Kodel","sequence":"additional","affiliation":[{"name":"Laboratory of Morphology and Experimental Pathology, Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49032-490, SE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-9634","authenticated-orcid":false,"given":"Klebson S.","family":"Santos","sequence":"additional","affiliation":[{"name":"Center for Study on Colloidal Systems (NUESC), Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49032-490, SE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete Z.","family":"Gomes","sequence":"additional","affiliation":[{"name":"Graduate Program in Biosciences and Health, Northeast Biotechnology Network (RENORBIO), Tiradentes University, Farol\u00e2ndia Campus, Av. Murilo Dantas, 300, Aracaju 49032-490, SE, Brazil"},{"name":"Laboratory of Morphology and Experimental Pathology, Institute of Technology and Research (ITP), Av. Murilo Dantas, 300, Aracaju 49032-490, SE, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pitton Rissardo, J., McGarry, A., Shi, Y., Fornari Caprara, A.L., and Kannarkat, G.T. (2025). Alpha-Synuclein Neurobiology in Parkinson\u2019s Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives. Brain Sci., 15.","DOI":"10.3390\/brainsci15121260"},{"key":"ref_2","first-page":"91","article-title":"Parkinson\u2019s Disease","volume":"Volume 4273","author":"Double","year":"2022","journal-title":"Neuroscience in the 21st Century: From Basic to Clinical"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"172","author":"Elbaz","year":"2016","journal-title":"Rev. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/15398285.2023.2212529","article-title":"Parkinson Disease","volume":"27","author":"Joseph","year":"2023","journal-title":"J. Consum. Health Internet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1017\/cjn.2019.287","article-title":"Falls in Synucleinopathies","volume":"47","author":"Joza","year":"2020","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Church, F.C., and Church, F.C. (2021). Treatment Options for Motor and Non-Motor Symptoms of Parkinson\u2019s Disease. Biomolecules, 11.","DOI":"10.3390\/biom11040612"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101834","DOI":"10.1016\/j.arr.2022.101834","article-title":"Premotor, nonmotor and motor symptoms of Parkinson\u2019s Disease: A new clinical state of the art","volume":"84","author":"Sallem","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.30044","article-title":"The Effect of Dysautonomia on Motor, Behavioral, and Cognitive Fluctuations in Parkinson\u2019s Disease","volume":"40","author":"Mahajan","year":"2025","journal-title":"Mov. Disord."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Beheshti, I., and Beheshti, I. (2025). Exploring Risk and Protective Factors in Parkinson\u2019s Disease. Cells, 14.","DOI":"10.3390\/cells14100710"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.amjmed.2019.03.001","article-title":"Parkinson\u2019s Disease and Parkinsonism","volume":"132","author":"Hayes","year":"2019","journal-title":"Am. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.bmcl.2017.07.075","article-title":"Current approaches to the treatment of Parkinson\u2019s Disease","volume":"27","author":"Ellis","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_12","unstructured":"Muranova, A., and Shanina, E. (2026, January 10). Levodopa\/Carbidopa\/Entacapone Combination Therapy, Available online: https:\/\/www.ncbi.nlm.nih.gov\/sites\/books\/NBK599508\/."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Minchev, D., Kazakova, M., and Sarafian, V. (2022). Neuroinflammation and autophagy in Parkinson\u2019s disease-novel perspectives. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314997"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101816","DOI":"10.1016\/j.arr.2022.101816","article-title":"Proteostasis in Parkinson\u2019s disease: Recent development and possible implication in diagnosis and therapeutics","volume":"84","author":"Kulkarni","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease\u2013a key disease hallmark with therapeutic potential","volume":"18","author":"Henrich","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fan, S.P., Okuzumi, A., Chen, P.S., Tai, Y.C., Kuo, Y.C., Tai, C.H., Li, C.H., Chiang, H.L., Hatano, T., and Lin, C.H. (J. Formos. Med. Assoc., 2025). Parkinson\u2019s disease in transition: Genetics, biomarkers, and emerging therapeutics, J. Formos. Med. Assoc., in press.","DOI":"10.1016\/j.jfma.2025.12.005"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev-cellbio-100818-125512","article-title":"Parkinson\u2019s: A disease of aberrant vesicle trafficking","volume":"36","author":"Singh","year":"2020","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.conb.2021.09.001","article-title":"Synaptic proteostasis in Parkinson\u2019s disease","volume":"72","author":"Nachman","year":"2022","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_19","first-page":"10","article-title":"Can alpha-synuclein be both the cause and a consequence of Parkinson\u2019s disease?","volume":"3","author":"Chen","year":"2023","journal-title":"Ageing Neurodegener. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41419-025-08076-z","article-title":"Are we ready for a biological diagnosis of Parkinson\u2019s Disease?","volume":"16","author":"Cimmino","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41531-025-01150-5","article-title":"A multi-dimensional view on the etiology of Parkinson\u2019s disease","volume":"11","author":"Bernhardt","year":"2025","journal-title":"npj Park. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41531-023-00461-9","article-title":"A proteogenomic view of Parkinson\u2019s disease causality and heterogeneity","volume":"9","author":"Kaiser","year":"2023","journal-title":"npj Park. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11795735241286821","DOI":"10.1177\/11795735241286821","article-title":"Transcriptomics profiling of Parkinson\u2019s disease progression subtypes reveals distinctive patterns of gene expression","volume":"17","author":"Fabrizio","year":"2025","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s43587-025-00818-0","article-title":"Large-scale proteomic analyses of incident Parkinson\u2019s disease reveal new pathophysiological insights and potential biomarkers","volume":"5","author":"Gan","year":"2025","journal-title":"Nat. Aging"},{"key":"ref_25","first-page":"899","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"Mcfarthing","year":"2024","journal-title":"J. Park. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease","volume":"272","author":"Alfaidi","year":"2025","journal-title":"J. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"125806","DOI":"10.1016\/j.jns.2026.125806","article-title":"\u03b1-synuclein monoclonal antibodies in Parkinson\u2019s disease: A failed promise or unmet potential?","volume":"482","author":"Messak","year":"2026","journal-title":"J. Neurol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.neurol.2017.10.003","article-title":"James Parkinson (1755\u20131824), one-man band, apothecary\u2013surgeon, philanthropist, medical popularizer, social reformer, political activist, chemist, geologist and paleontologist","volume":"173","author":"Poirier","year":"2017","journal-title":"Rev. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1017\/cjn.2017.270","article-title":"A Tribute to James Parkinson","volume":"45","author":"Parent","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ageing\/afx196","article-title":"200 Years of Parkinson\u2019s disease: What have we learnt from James Parkinson?","volume":"47","author":"Mcdonald","year":"2018","journal-title":"Age Ageing"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104579","DOI":"10.1016\/j.nbd.2019.104579","article-title":"Dystonia and levodopa-induced dyskinesias in Parkinson\u2019s disease: Is there a connection?","volume":"132","author":"Calabresi","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gnanaraj, C., Sekar, M., Fuloria, S., Swain, S.S., Gan, S.H., Chidambaram, K., Rani, N.N.I.M., Balan, T., Stephenie, S., and Lum, P.T. (2022). In Silico Molecular Docking Analysis of Karanjin against Alzheimer\u2019s and Parkinson\u2019s Diseases as a Potential Natural Lead Molecule for New Drug Design, Development and Therapy. Molecules, 27.","DOI":"10.3390\/molecules27092834"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.neurol.2018.08.004","article-title":"The genetic landscape of Parkinson\u2019s disease","volume":"174","author":"Lunati","year":"2018","journal-title":"Rev. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1590\/0004-282x-anp-2020-0409","article-title":"Genetics of Parkinson\u2019s disease in Brazil: A systematic review of monogenic forms","volume":"79","author":"Mata","year":"2021","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Su, R., and Zhou, T. (2021). Alpha-Synuclein Induced Immune Cells Activation and Associated Therapy in Parkinson\u2019s Disease. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.769506"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Day, J., and Mullin, S. (2021). The Genetics of Parkinson\u2019s Disease and Implications for Clinical Practice. Genes, 12.","DOI":"10.3390\/genes12071006"},{"key":"ref_37","first-page":"3","article-title":"Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis","volume":"1","author":"Kouli","year":"2018","journal-title":"Exon Publ."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Huang, M., Bargues-Carot, A., Riaz, Z., Wickham, H., Zenitsky, G., Jin, H., Anantharam, V., Kanthasamy, A., and Kanthasamy, A.G. (2022). Impact of Environmental Risk Factors on Mitochondrial Dysfunction, Neuroinflammation, Protein Misfolding, and Oxidative Stress in the Etiopathogenesis of Parkinson\u2019s Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810808"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40035-019-0165-9","article-title":"The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson\u2019s disease","volume":"8","author":"Pang","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.26467","article-title":"Effect Modification between Genes and Environment and Parkinson\u2019s Disease Risk","volume":"92","author":"Brolin","year":"2022","journal-title":"Ann. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101857","DOI":"10.1016\/j.arr.2023.101857","article-title":"Immunity orchestrates a bridge in gut-brain axis of neurodegenerative diseases","volume":"85","author":"Cheng","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"122022","DOI":"10.1016\/j.lfs.2023.122022","article-title":"Unveiling the role of gut-brain axis in regulating neurodegenerative diseases: A comprehensive review","volume":"330","author":"Yadav","year":"2023","journal-title":"Life Sci."},{"key":"ref_45","first-page":"S113","article-title":"Inflammasome Activation in Parkinson\u2019s Disease","volume":"12","author":"Jewell","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.tibs.2018.11.005","article-title":"The Cellular Environment Affects Monomeric \u03b1-Synuclein Structure","volume":"44","author":"Stephens","year":"2019","journal-title":"Trends Biochem. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13195-022-01150-0","article-title":"Alpha-synuclein: A pathological factor with A\u03b2 and tau and biomarker in Alzheimer\u2019s disease","volume":"14","author":"Shim","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Arias-Carri\u00f3n, O., Guerra-Crespo, M., Padilla-God\u00ednez, F.J., Soto-Rojas, L.O., and Manjarrez, E. (2025). \u03b1-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202504.2181.v1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1038\/s41467-020-16564-3","article-title":"Extent of N-terminus exposure of monomeric alpha-synuclein determines its aggregation propensity","volume":"11","author":"Stephens","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1021\/acs.chemrev.8b00731","article-title":"Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates","volume":"119","author":"Ilie","year":"2019","journal-title":"Chem. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1021\/acschemneuro.9b00053","article-title":"Molecular Simulations Reveal Terminal Group Mediated Stabilization of Helical Conformers in Both Amyloid-\u03b242 and \u03b1-Synuclein","volume":"10","author":"Bhattacharya","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108870","DOI":"10.1016\/j.neuropharm.2021.108870","article-title":"Targeting alpha-synuclein via the immune system in Parkinson\u2019s disease: Current vaccine therapies","volume":"202","author":"Fleming","year":"2022","journal-title":"Neuropharmacology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Del Rey, N.L.G., Quiroga-Varela, A., Garbayo, E., Carballo-Carbajal, I., Fern\u00e1ndez-Santiago, R., Monje, M.H.G., Trigo-Damas, I., Blanco-Prieto, M.J., and Blesa, J. (2018). Advances in parkinson\u2019s disease: 200 years later. Front. Neuroanat., 12.","DOI":"10.3389\/fnana.2018.00113"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","article-title":"\u03b1-Synuclein pathology in Parkinson\u2019s disease and related \u03b1-synucleinopathies","volume":"709","author":"Henderson","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tins.2022.11.007","article-title":"\u03b1-Synuclein in synaptic function and dysfunction","volume":"46","author":"Sharma","year":"2023","journal-title":"Trends Neurosci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"106736","DOI":"10.1016\/j.bpc.2021.106736","article-title":"Intermediates of \u03b1-synuclein aggregation: Implications in Parkinson\u2019s disease pathogenesis","volume":"281","author":"Gadhe","year":"2022","journal-title":"Biophys. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Fan, T.-S., Liu, S.C.-H., Wu, R.M., Fan, T.S., Liu, S.C.H., and Wu, R.M. (2021). Alpha-Synuclein and Cognitive Decline in Parkinson Disease. Life, 11.","DOI":"10.3390\/life11111239"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/pro.630","article-title":"Structures of segments of \u03b1-synuclein fused to maltose-binding protein suggest intermediate states during amyloid formation","volume":"20","author":"Zhao","year":"2011","journal-title":"Protein Sci."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Eo, H., Kim, S., Jung, U.J., and Kim, S.R. (2024). Alpha-Synuclein and Microglia in Parkinson\u2019s Disease: From Pathogenesis to Therapeutic Prospects. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237243"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"105890","DOI":"10.1016\/j.parkreldis.2023.105890","article-title":"Abnormal immune function of B lymphocyte in peripheral blood of Parkinson\u2019s disease","volume":"116","author":"Zhang","year":"2023","journal-title":"Park. Relat. Disord."},{"key":"ref_61","first-page":"S105","article-title":"Microglia in Parkinson\u2019s Disease","volume":"12","author":"Stefanova","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13024-019-0335-3","article-title":"Microglia affect \u03b1-synuclein cell-to-cell transfer in a mouse model of Parkinson\u2019s disease","volume":"14","author":"George","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/jcp.26865","article-title":"Oxidative stress and neuroinflammation in the story of Parkinson\u2019s disease: Could targeting these pathways write a good ending?","volume":"234","author":"Hassanzadeh","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12974-023-02723-y","article-title":"The reciprocal interactions between microglia and T cells in Parkinson\u2019s disease: A double-edged sword","volume":"20","author":"Xu","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"578019","DOI":"10.1016\/j.jneuroim.2023.578019","article-title":"Microglial depletion exacerbates motor impairment and dopaminergic neuron loss in a 6-OHDA model of Parkinson\u2019s disease","volume":"375","author":"Pereira","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Murakami, H., Ono, K., Shiraishi, T., Umehara, T., Omoto, S., and Iguchi, Y. (2021). Mini Review: Correlations of Cognitive Domains with Cerebrospinal Fluid \u03b1-Synuclein Levels in Patients with Parkinson\u2019s Disease. Front. Aging Neurosci., 12.","DOI":"10.3389\/fnagi.2020.616357"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00281-022-00947-3","article-title":"The immunology of Parkinson\u2019s disease","volume":"44","author":"Zhu","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Li, Y., Xia, Y., Yin, S., Wan, F., Hu, J., Kou, L., Sun, Y., Wu, J., Zhou, Q., and Huang, J. (2021). Targeting Microglial \u03b1-Synuclein\/TLRs\/NF-kappaB\/NLRP3 Inflammasome Axis in Parkinson\u2019s Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.719807"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e28838","DOI":"10.1016\/j.heliyon.2024.e28838","article-title":"Role of NLRP3 in Parkinson\u2019s disease: Specific activation especially in dopaminergic neurons","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"key":"ref_70","first-page":"S65","article-title":"T Lymphocytes in Parkinson\u2019s Disease","volume":"12","author":"Contaldi","year":"2022","journal-title":"J. Park. Dis."},{"key":"ref_71","first-page":"72","article-title":"T-cell based immunotherapies for Parkinsons disease","volume":"1","author":"Pacheco","year":"2021","journal-title":"Open Explor."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine Adjuvants: From 1920 to 2015 and Beyond","volume":"3","author":"Preiss","year":"2015","journal-title":"Vaccines"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Laera, D., HogenEsch, H., and O\u2019Hagan, D.T. (2023). Aluminum adjuvants-\u2018Back to the Future\u2019. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15071884"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Verma, S.K., Mahajan, P., Singh, N.K., Gupta, A., Aggarwal, R., Rappuoli, R., and Johri, A.K. (2023). New-age vaccine adjuvants, their development, and future perspective. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1043109"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Sander, V.A., Corigliano, M.G., and Clemente, M. (2019). Promising plant-derived adjuvants in the development of coccidial vaccines. Front. Vet. Sci., 6.","DOI":"10.3389\/fvets.2019.00020"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.dscb.2021.100018","article-title":"Effects of bromelain on striatal neuroinflammation in rat model of Parkinsonism","volume":"3","author":"Adu","year":"2021","journal-title":"Brain Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.19070\/2377-8075-21000493","article-title":"Citation: Jayashri Prabakar, Sathya Kumaresan, Pradeep Kumarr. In Vitro Evaluation Of Cytotoxicity and Antioxidant Efficacy Of Bromelain","volume":"8","author":"Prabakar","year":"2021","journal-title":"Int. J. Dent. Oral Sci."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Pezzani, R., Jim\u00e9nez-Garcia, M., Cap\u00f3, X., S\u00f6nmez G\u00fcrer, E., Sharopov, F., Rachel, T.Y.L., Ntieche Woutouoba, D., Rescigno, A., Peddio, S., and Zucca, P. (2023). Anticancer properties of bromelain: State-of-the-art and recent trends. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1068778"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"109675","DOI":"10.1016\/j.foodres.2020.109675","article-title":"Pineapple (Ananas comosus): A comprehensive review of nutritional values, volatile compounds, health benefits, and potential food products","volume":"137","author":"Mohd","year":"2020","journal-title":"Food Res. Int."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.15557\/PiMR.2018.0013","article-title":"Prozdrowotne w\u0142a\u015bciwo\u015bci ananasa Health-promoting properties of pineapple","volume":"14","author":"Zdrojewicz","year":"2018","journal-title":"Pediatr. Med. Rodz."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s12031-021-01818-6","article-title":"Modification of Glial Cell Activation through Dendritic Cell Vaccination: Promises for Treatment of Neurodegenerative Diseases","volume":"71","author":"Sabahi","year":"2021","journal-title":"J. Mol. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s10571-018-0598-1","article-title":"Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders","volume":"38","author":"Brezovakova","year":"2018","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jneuroim.2015.08.008","article-title":"Alzheimer\u2019s disease vaccine development: A new strategy focusing on immune modulation","volume":"287","author":"Marciani","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"7711","DOI":"10.1007\/s11033-021-06779-y","article-title":"Neuroprotective effect of bromelain in 6-hydroxydopamine induced in vitro model of Parkinson\u2019s disease","volume":"48","author":"Okkay","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4454744","DOI":"10.1155\/2024\/4454744","article-title":"Proteomics and Its Current Application in Biomedical Area: Concise Review","volume":"2024","author":"Gobena","year":"2024","journal-title":"Sci. World J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature15368","article-title":"Structure of the toxic core of \u03b1-synuclein from invisible crystals","volume":"525","author":"Rodriguez","year":"2015","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e4875","DOI":"10.1002\/pro.4875","article-title":"Structural insights into the unique recognition module between \u03b1-synuclein peptide and nanobody","volume":"33","author":"Islam","year":"2024","journal-title":"Protein Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40259-024-00646-5","article-title":"Recombinant Antibody Fragments for Immunotherapy of Parkinson\u2019s Disease","volume":"38","author":"Manoutcharian","year":"2024","journal-title":"BioDrugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived \u03b1-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson\u2019s disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41531-024-00822-y","article-title":"Structural basis of epitope recognition by anti-alpha-synuclein antibodies MJFR14-6-4-2","volume":"10","author":"Reimer","year":"2024","journal-title":"npj Park. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1002\/anie.201914878","article-title":"The Molecular Basis of the Interaction of Cyclophilin A with \u03b1-Synuclein","volume":"59","author":"Favretto","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4939-9124-2_16","article-title":"Detection of \u03b1-Synuclein in Biological Samples Using Mass Spectrometry","volume":"1948","author":"Brinkmalm","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"102988","DOI":"10.1016\/j.jddst.2021.102988","article-title":"Nanovaccine for transdermal delivery system","volume":"67","author":"Dewangan","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"12530","DOI":"10.1002\/jcp.28120","article-title":"Nanovaccine: A novel approach in immunization","volume":"234","author":"Darroudi","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"106944","DOI":"10.1016\/j.intimp.2020.106944","article-title":"Therapeutic vaccines for colorectal cancer: The progress and future prospect","volume":"88","author":"Shahnazari","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40005-021-00521-3","article-title":"Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson\u2019s disease","volume":"51","author":"Duwa","year":"2021","journal-title":"J. Pharm. Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bbi.2022.01.007","article-title":"Neurodegeneration by \u03b1-synuclein-specific T cells in AAV-A53T-\u03b1-synuclein Parkinson\u2019s disease mice","volume":"101","author":"Karikari","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"120510","DOI":"10.1016\/j.jns.2022.120510","article-title":"Unaltered T cell responses to common antigens in individuals with Parkinson\u2019s disease","volume":"444","author":"Williams","year":"2023","journal-title":"J. Neurol. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(20)30136-8","article-title":"Safety and immunogenicity of the \u03b1-synuclein active immunotherapeutic PD01A in patients with Parkinson\u2019s disease: A randomised, single-blinded, phase 1 trial","volume":"19","author":"Volc","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: Implications for Parkinson\u2019s disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_103","first-page":"1079","article-title":"Safety and Tolerability of Active Immunotherapy Targeting \u03b1-Synuclein with PD03A in Patients with Early Parkinson\u2019s Disease: A Randomized, Placebo-Controlled, Phase 1 Study","volume":"11","author":"Poewe","year":"2021","journal-title":"J. Park. Dis."},{"key":"ref_104","unstructured":"(2026, January 10). A Study to Evaluate the Effects of ACI-7104.056 Vaccination in Patients with Early Stages of Parkinson\u2019s Disease (VacSYn), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06015841."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti\u2013\u03b1-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov. Disord."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of Cinpanemab in Early Parkinson\u2019s Disease","volume":"387","author":"Lang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00401-021-02381-5","article-title":"Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric \u03b1-synuclein accumulation in the brain and gut","volume":"143","author":"Nimmo","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"104582","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/mds.29784","article-title":"Randomized Phase I Trial of the \u03b1-Synuclein Antibody Lu AF82422","volume":"39","author":"Buur","year":"2024","journal-title":"Mov. Disord."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.nbas.2023.100086","article-title":"Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against \u03b1-synuclein oligomers\/protofibrils","volume":"4","author":"Aniszewska","year":"2023","journal-title":"Aging Brain"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jcph.6103","article-title":"Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti-\u03b1-Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults","volume":"64","author":"Bachhav","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of Prasinezumab in Early-Stage Parkinson\u2019s Disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41746-025-01572-8","article-title":"Exploratory digital outcome measures of motor sign progression in Parkinson\u2019s disease patients treated with prasinezumab","volume":"8","author":"Taylor","year":"2025","journal-title":"npj Digit. Med."},{"key":"ref_114","unstructured":"Pfeifer, A., and Ayer, M. (2023). Anti-Alpha-Synuclein Therapeutic Vaccines. (WO2023152260)."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1080\/14760584.2023.2274479","article-title":"Vaccine approaches for antigen capture by liposomes","volume":"22","author":"Zhou","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"ref_116","unstructured":"Barbour, R., Kinney, G., and Zago, W. (2022). Alpha-Synuclein Vaccine for the Treatment of Synucleinopathies. (WO2022060487A1)."},{"key":"ref_117","unstructured":"Cao, C., and Lin, X. (2017). Methods, Antibodies, and Vaccines Utilizing Epitopes of Alpha Synuclein for Treatment of Parkinsons Disease. (US20170196948A1)."},{"key":"ref_118","unstructured":"Lannfelt, L., Bergstr\u00f6m, J., Ingelsson, M., and Gellerfors, P. (2009). Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders. (WO2009133521A2)."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/12\/2036\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:14:36Z","timestamp":1781324076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/12\/2036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":118,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["molecules31122036"],"URL":"https:\/\/doi.org\/10.3390\/molecules31122036","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}